ABSTRACT
TOPIC: Systematic literature review of treatment efficacy of previously used protocols in treating patients with proven cancer-associated retinopathy (CAR). CLINICAL RELEVANCE: There is no universally accepted treatment algorithm for CAR and visual prognosis is very poor. We describe a patient with CAR with dramatic improvement in vision after treatment with high doses of corticosteroids followed by plasma exchange (PLEX) and present results of a systematic literature review of treatment efficacy of previously used protocols in treating patients with proven CAR. METHODS: We describe a 70-year-old man with CAR who demonstrated dramatic improvement in vision after treatment with high doses of systemic corticosteroids followed by 7 sessions of PLEX. We then report the results of a systematic review of all previously published English literature discussing visual outcomes of various treatment regimens used for patients with antibody-proven CAR. RESULTS: The index patient is a rare case of CAR with sustained significant improvement in vision after treatment with high doses of corticosteroids followed by PLEX. The systematic review identified 28 antibody-proven cases of CAR, 27 of which were treated with steroids, which resulted in varying degrees of improvement in visual acuity in 59% (16 of 27). The time from symptom onset to initiation of treatment and the dose of steroids did not influence the visual outcome. Three patients were also treated with PLEX in addition to steroids, and 2 of 3 patients demonstrated improvement in vision; however, there was no difference in visual outcome in patients treated with steroids only versus those treated with steroids + PLEX. CONCLUSION: Treatment with steroids or steroids + PLEX resulted in some improvements in visual acuity in 59% of patients. Removal of antirecoverin antibodies with PLEX can arrest the immune attack on the photoreceptors and potentially improve visual function; thus, it should be considered in addition to steroids. Further studies with larger cohorts are needed to establish a treatment protocol and further determine the effectiveness of the different approaches. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Subject(s)
Paraneoplastic Syndromes, Ocular , Male , Humans , Aged , Paraneoplastic Syndromes, Ocular/diagnosis , Paraneoplastic Syndromes, Ocular/drug therapy , Paraneoplastic Syndromes, Ocular/etiology , Plasma Exchange/methods , Treatment Outcome , Prognosis , Steroids/therapeutic useABSTRACT
PURPOSE: Melanoma-associated retinopathy responds poorly to currently-available therapies, with continued chronic decline in visual function being the norm, despite treatment. The purpose of this report is to describe the excellent response of a patient with melanoma-associated retinopathy to a triple therapy regimen of rituximab, intravenous immunoglobulin, and intravitreal corticosteroids. METHODS: Single interventional case report describing management of melanoma-associated retinopathy and the patient's response to this treatment. Retinal function was monitored by serial visual acuity, fundus exams, Goldmann visual fields, and electroretinography. RESULTS: A 65-year old man presented with new onset photopsia, decrease visual acuity and nyctalopia in both eyes in the setting of recently-diagnosed Stage IIIB melanoma, initially treated with wide local excision and adjuvant interferon. He was diagnosed with melanoma-associated retinopathy that initially worsened during his course of interferon for treatment of the melanoma. We initiated triple therapy with rituximab, intravenous immunoglobulin, and intravitreal corticosteroids, and this resulted in full return of electroretinography function and resumption of 20/20 visual acuity in both eyes. CONCLUSION: This is the first reported case of the utility of triple therapy with rituximab, intravenous immunoglobulin, and intravitreal steroids for successful management of melanoma-associated retinopathy as demonstrated by improvement in acuity, symptoms, visual fields, and electroretinography.
Subject(s)
Melanoma , Paraneoplastic Syndromes, Ocular , Male , Humans , Aged , Paraneoplastic Syndromes, Ocular/diagnosis , Paraneoplastic Syndromes, Ocular/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Rituximab/therapeutic use , Electroretinography , Melanoma/complications , Melanoma/drug therapy , Adrenal Cortex Hormones , Steroids , InterferonsABSTRACT
Purpose: To report a case of cancer-associated retinophaty (CAR) treated with intravenous immunoglobulin (IGIV) and review the use of IGIV in the treatment of CARMethods: Case report: A 68-year-old woman, former smoker, presented with bilateral subacute decreased visual acuity with 1 month of evolution, without other symptoms. Clinical examination revealed retinal atrophy and a mild vitritis component. Treatment with corticosteroid and IGIV was initiated empirically with the stabilization of visual loss. Anti-recoverin antibodies tested positive and a small cell lung carcinoma was diagnosed. In a review of the literature, we found that only 12 cases of patients treated with intravenous immunoglobulins have been reported.Conclusions: the early use of IVIG could contribute to an improvement and/or stabilization of visual symptoms in this patient group due to its rapid effect and lower profile of adverse effects when administered with chemotherapy.
Subject(s)
Carcinoma, Small Cell/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Lung Neoplasms/drug therapy , Paraneoplastic Syndromes, Ocular/drug therapy , Retina/diagnostic imaging , Retinal Diseases/drug therapy , Aged , Female , Fluorescein Angiography/methods , Fundus Oculi , Humans , Immunologic Factors/therapeutic use , Paraneoplastic Syndromes, Ocular/diagnosis , Retinal Diseases/diagnosis , Retinal Diseases/etiology , Tomography, Optical Coherence/methodsABSTRACT
PURPOSE: To describe a case of choroidal neovascularization (CNV) and chorioretinal scarring in a patient with melanoma-associated retinopathy after ipilimumab/nivolumab combination immune therapy for malignant melanoma. METHODS: Retrospective case report with fundus photography, fluorescein angiography, optical coherence tomography, and electroretinography. RESULTS: A 65-year-old woman presented with symptoms of photopsia and visual field loss. She had previously undergone ipilimumab/nivolumab combination chemotherapy treatment for malignant melanoma 14 months earlier coinciding with the onset of her visual symptoms. Fundus photography showed bilateral atrophic chorioretinal lesions and peripheral retinal pigment epithelial changes. Fluorescein angiography revealed retinovascular leakage in both eyes with CNV in the right eye. Optical coherence tomography showed a pigment epithelial detachment with subretinal fluid and subretinal hyperreflective material consistent with occult CNV. Visual field testing showed generalized visual field loss in both eyes. Bloodwork discovered an elevated angiotensin-converting enzyme. Electroretinography revealed abnormal peripheral rod and cone function with impairment of the photoreceptor and inner nuclear layer. Serum Western blot was positive for 60 kDa antiretinal autoantibody. After a single bevacizumab injection in the right eye, CNV resolved and visual acuity improved from 20/50 before the injection to 20/25 3 months after the injection. Visual acuity in the left eye deteriorated for months to counting fingers but then improved to 20/100 on follow-up examinations. CONCLUSION: Ipilimumab and nivolumab have been associated with immune-related ocular adverse effects. We report a case of combination therapy presenting with chorioretinal scarring and subsequent CNV in a patient with melanoma-associated retinopathy, a rare yet important adverse effect.
Subject(s)
Choroid Diseases , Choroidal Neovascularization , Paraneoplastic Syndromes, Ocular , Aged , Choroid Diseases/chemically induced , Choroid Diseases/diagnostic imaging , Choroidal Neovascularization/chemically induced , Choroidal Neovascularization/diagnostic imaging , Drug Therapy, Combination/adverse effects , Female , Fluorescein Angiography , Humans , Ipilimumab/adverse effects , Nivolumab/adverse effects , Paraneoplastic Syndromes, Ocular/drug therapy , Retrospective Studies , Tomography, Optical CoherenceABSTRACT
PURPOSE: Melanoma-associated retinopathy (MAR) is a rare paraneoplastic syndrome due to antibodies targeting bipolar retinal cells. Its evolution, particularly in patients treated with immune checkpoint inhibitors (ICI), is currently poorly understood. In the few cases published, patients' visual function got worse when these molecules were prescribed. Here, we present a case of a patient with severe MAR treated with an ICI for melanoma progression. METHODS: A 68-year-old woman with a history of melanoma of the palpebral conjunctiva presented with sudden and gradually worsening visual disturbances. Simultaneously, a metastatic evolution of the melanoma was diagnosed and surgically treated exclusively. Visual acuity assessment, static automated perimetry and ERG results lead to the diagnosis of MAR. Since systemic corticosteroid therapy did not improve her symptoms, repeated intraocular corticosteroid injections were performed with a positive outcome. Later on, metastatic progression of the patient's melanoma led to the introduction of pembrolizumab, an ICI targeting PD-1. Immunotherapy has changed the prognosis of patient affected by metastatic melanoma, but these molecules may induce various immune-related adverse effects. In our case, intraocular corticosteroid injections were still performed simultaneously. Visual acuity assessment, static automated perimetry and ERG were performed during the course of this treatment. RESULTS: Full-field ERGs results suggested the possibility that the ophthalmologic treatment might restore the patient's retinal function despite the continued immunotherapy. CONCLUSION: We report the first case of MAR with a positive outcome after 1 year of ICI, possibly thanks to intravitreal corticosteroid therapy.
Subject(s)
Paraneoplastic Syndromes, Ocular , Skin Neoplasms , Aged , Antibodies, Monoclonal, Humanized , Dexamethasone/therapeutic use , Electroretinography , Female , Humans , Intravitreal Injections , Paraneoplastic Syndromes, Ocular/diagnosis , Paraneoplastic Syndromes, Ocular/drug therapyABSTRACT
PURPOSE: To report a patient who presented with red eye and diffuse palpebral conjunctival thickening and papillary growth bilaterally. METHODS: A 63-year-old woman with a medical history of stage IV adenocarcinoma of the lung with metastasis to the bone, the lung, and the lymph nodes presented with redness and irritation of both eyes for 3 months. The patient has been treated with topical corticosteroids for 3 weeks with no relief of symptoms. RESULTS: Clinical examination and pathology report of conjunctival biopsy confirmed the diagnosis of conjunctival acanthosis nigricans. CONCLUSIONS: Conjunctival acanthosis nigricans is a rare paraneoplastic condition that resembles papilloma and can present a challenge in diagnosis. When acanthosis nigricans occurs after the diagnosis of malignancy, it can be an indicator of progression of the underlying condition. The diagnosis of conjunctival acanthosis nigricans in a patient with no history of cancer should prompt clinicians for further malignancy workup.
Subject(s)
Acanthosis Nigricans/diagnosis , Adenocarcinoma/secondary , Bone Neoplasms/secondary , Conjunctival Neoplasms/diagnosis , Lung Neoplasms/pathology , Lymphatic Metastasis , Paraneoplastic Syndromes, Ocular/diagnosis , Acanthosis Nigricans/drug therapy , Conjunctival Neoplasms/drug therapy , Female , Glucocorticoids/therapeutic use , Humans , Middle Aged , Paraneoplastic Syndromes, Ocular/drug therapyABSTRACT
PURPOSE: Collapsin response-mediator protein 5 (CRMP5) immunoglobulin G (IgG) has been associated with paraneoplastic optic neuritis, vitritis, retinitis, or a combination thereof, but few reports of these findings exist in the literature. We reviewed the neuro-ophthalmic findings and visual outcomes in a large series of CRMP5 IgG-positive patients to characterize further its clinical phenotype and response to treatment. DESIGN: Retrospective case series. PARTICIPANTS: Seventy-six patients with CRMP5 autoimmunity examined at the Mayo Clinic, Rochester, Minnesota. METHODS: Single academic medical center chart review of all CRMP5 IgG-positive (serum titer, >1:240) patients seen between 2001 and 2017. MAIN OUTCOME MEASURES: Neuro-ophthalmic manifestations and outcomes of CRMP5 autoimmunity, coexisting neural autoantibody presence and paraneoplastic associations, and the impact of immunosuppressant therapy. RESULTS: Twenty-nine of 76 patients (38%) demonstrated neuro-ophthalmic manifestations. Of the 29 patients with neuro-ophthalmic findings, the median age was 67 years (range, 33-88 years) and 20 (69%) were women. Cancer was diagnosed in 62% of the patients (small-cell carcinoma in 83%). Neuro-ophthalmic symptoms occurred before the diagnosis of cancer in 72%. Seventeen of 29 patients (59%) showed ocular (i.e., anterior visual pathway or intraocular) manifestations; presenting median visual acuity was 20/50 (range, 20/20-counting fingers) and the final median visual acuity was 20/40 (range, 20/20-hand movements). Fourteen of 17 patients (82%) demonstrated optic neuropathy, with 12 of these patients also showing retinitis or uveitis. Three of 17 patients (18%) showed retinitis or uveitis without optic neuropathy. All 12 patients with optic neuropathy and a documented fundus examination at visual symptom onset demonstrated optic disc edema. No patients showed optic nerve enhancement on magnetic resonance imaging. Twelve of 29 patients (41%) demonstrated ocular motility dysfunction consisting of central nystagmus and diplopia. Among those receiving immunosuppressive therapy, visual function improved in 50%. CONCLUSIONS: In our cohort of 29 CRMP5 IgG-positive patients with neuro-ophthalmic manifestations, optic neuropathy presented with optic disc edema, often associated with uveitis, retinitis, or both. The combination of retinitis, vitritis, and optic disc edema without optic nerve enhancement should prompt serologic testing for CRMP5 IgG to expedite vision-sparing immunosuppressant therapy and a targeted search for a systemic cancer.
Subject(s)
Autoantibodies/blood , Eye Diseases/immunology , Hydrolases/immunology , Microtubule-Associated Proteins/immunology , Papilledema/immunology , Paraneoplastic Syndromes, Ocular/immunology , Retinitis/immunology , Vitreous Body/immunology , Adult , Aged , Aged, 80 and over , Eye Diseases/diagnosis , Eye Diseases/drug therapy , Female , Fluorescent Antibody Technique, Indirect , Glucocorticoids/therapeutic use , Humans , Immunoglobulin G/blood , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Papilledema/diagnosis , Papilledema/drug therapy , Paraneoplastic Syndromes, Ocular/diagnosis , Paraneoplastic Syndromes, Ocular/drug therapy , Retinitis/diagnosis , Retinitis/drug therapy , Retrospective Studies , Visual Acuity/physiology , Visual Fields/physiology , Vitreous Body/drug effects , Vitreous Body/pathologySubject(s)
Intraocular Lymphoma/pathology , Lymphoma, Large B-Cell, Diffuse/pathology , Paraneoplastic Syndromes, Ocular/pathology , Retinal Neoplasms/pathology , Antimetabolites, Antineoplastic/therapeutic use , Female , Fluorescein Angiography , Humans , Intraocular Lymphoma/diagnosis , Intraocular Lymphoma/drug therapy , Intravitreal Injections , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/drug therapy , Methotrexate/therapeutic use , Middle Aged , Paraneoplastic Syndromes, Ocular/diagnosis , Paraneoplastic Syndromes, Ocular/drug therapy , Retinal Neoplasms/diagnosis , Retinal Neoplasms/drug therapy , Tomography, Optical Coherence , Visual AcuitySubject(s)
Antigens/immunology , Autoantibodies/immunology , Dexamethasone/administration & dosage , Paraneoplastic Syndromes, Ocular/drug therapy , Recoverin/immunology , Retina/immunology , Autoantibodies/blood , Drug Implants , Fluorescein Angiography , Fundus Oculi , Glucocorticoids/administration & dosage , Humans , Intravitreal Injections , Male , Middle Aged , Paraneoplastic Syndromes, Ocular/diagnosis , Paraneoplastic Syndromes, Ocular/immunology , Recoverin/blood , Retina/diagnostic imaging , Tomography, Optical CoherenceABSTRACT
Importance: Bilateral diffuse uveal melanocytic proliferation is a rare sign of several systemic malignant neoplasms. Observations: A patient presenting with uveal melanocytic proliferation underwent a detailed physical examination and extensive imaging. No systemic malignant neoplasm was found. Chorioretinal biopsy was performed, and its immunohistochemical results revealed the presence of primary vitreoretinal lymphoma. Conclusions and Relevance: This patient's results suggest that diffuse uveal melanocytic proliferation may be associated not just with systemic malignant disease, but also with primary intraocular tumors, in this case a primary vitreoretinal lymphoma.
Subject(s)
Cell Proliferation , Lymphoma, Large B-Cell, Diffuse/pathology , Melanocytes/pathology , Paraneoplastic Syndromes, Ocular/pathology , Retinal Neoplasms/pathology , Uvea/pathology , Vitreous Body/pathology , Antimetabolites, Antineoplastic/therapeutic use , Biomarkers, Tumor/metabolism , Female , Fluorescein Angiography , Humans , Infusions, Intravenous , Intravitreal Injections , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/metabolism , Methotrexate/therapeutic use , Middle Aged , Neoplasm Proteins/metabolism , Paraneoplastic Syndromes, Ocular/drug therapy , Paraneoplastic Syndromes, Ocular/metabolism , Retinal Neoplasms/drug therapy , Retinal Neoplasms/metabolism , Tomography, Optical Coherence , Visual Acuity/physiology , Vitreous Body/drug effects , Vitreous Body/metabolismABSTRACT
Importance: Melanoma-associated retinopathy (MAR) is a paraneoplastic syndrome in which antiretinal antibodies crossreact with retinal ON-bipolar cells, resulting in night blindness and progressive visual field loss. Current therapeutic options include cytoreductive surgery in combination with immunoglobulin, corticosteroids, or plasmapheresis, but their effectiveness is limited and may be contraindicated, given the possible protective role of circulating autoantibodies against metastatic spread. We report 3-year follow-up of the first case (to our knowledge) of MAR treated with intravitreal long-acting steroid implants. Objective: To report on a patient with MAR who was treated with intravitreal fluocinolone acetonide implants in the absence of systemic immunosuppression. Design, Setting, and Participants: This is a 3-year follow-up of a 73-year-old woman with a history of surgical excision of a malignant melanoma of the left pinna who presented with visual symptoms of shimmering and nyctalopia. Fundus examination, fundus autofluorescence, and optical coherence tomography were normal, with no evidence of cystoid macular edema. Automated perimetry showed a reduction in visual field and full-field electroretinography (ERG) demonstrated findings consistent with generalized ON-bipolar cell dysfunction, typical of MAR. The patient was treated with bilateral fluocinolone acetonide intravitreal implants. Main Outcomes and Measures: Visual acuity, visual field, and electroretinography testing for 3 years after treatment. Results: Visual fields improved in this 73-year-old patient from 20/30 (Snellen measured as 6/9) OD and 20/16 (6/5) OS at baseline to 20/20 OU within 1 week of treatment. Detailed electroretinography monitoring indicated characteristic abnormalities that partly resolved after treatment, consistent with improved inner retinal ON-bipolar cell function. Bilateral cataracts developed approximately 2 years after injection; cataract surgery was performed uneventfully. At 3 years posttreatment, the patient remained visually stable and in systemic disease remission, with best-corrected visual acuity remaining at 20/20 OU. Conclusions and Relevance: We report what is, to our knowledge, the first case of MAR treated with intravitreal slow-release corticosteroid implants, which shows improvements in visual symptoms, visual fields, and retinal function. Sustained-release intraocular steroid implants may offer an effective and safe alternative to systemic immunosuppression in MAR, although results from 1 case should be generalized with abundant caution.
Subject(s)
Fluocinolone Acetonide/administration & dosage , Melanoma/complications , Paraneoplastic Syndromes, Ocular/drug therapy , Retinal Diseases/drug therapy , Skin Neoplasms/complications , Visual Acuity , Aged , Delayed-Action Preparations , Drug Implants , Electroretinography , Female , Fluorescein Angiography , Follow-Up Studies , Fundus Oculi , Glucocorticoids/administration & dosage , Humans , Immunosuppression Therapy , Intravitreal Injections , Melanoma/diagnosis , Paraneoplastic Syndromes, Ocular/diagnosis , Retinal Diseases/diagnosis , Retinal Diseases/etiology , Skin Neoplasms/diagnosis , Tomography, Optical Coherence , Visual FieldsABSTRACT
BACKGROUND: The use of molecularly targeted therapy is becoming widespread in oncology. These agents cause tumour-specific genetic alterations in signal transduction pathways, hence less generalised toxicity. Dabrafenib, a BRAF inhibitor and Trametinib, a MEK inhibitor are two molecularly targeted agents recently approved for treatment of advanced, unresectable melanomas. MEK retinopathy is a recently introduced term describing retinal toxicity secondary to MEK inhibitors. CASE PRESENTATION: A 71-year-old man presented with 'circular, green patches' in his central vision for 2 weeks. He had multiple relapsed stage IV BRAF gene mutant malignant melanoma. He was on treatment with Dabrafenib (Tafinlar) for 7 months and Trametinib (Mekinist) for 4 months respectively. The fundus looked normal. The OCT scan showed bilateral symmetrical cystoid macular edema, intraretinal and subretinal fluid, thickening of elliposoid zone and subretinal granular deposits. The symptoms resolved with temporary cessation of chemotherapy but OCT signs persisted. CONCLUSION: This case report identifies two new remarkable features of MEK retinopathy as thickening of ellipsoid zone and 'starry sky' pattern of distribution of subretinal granular deposits. These changes signify photoreceptors/ RPE toxicity and dysfunction. The subretinal granular deposits showed increased autofluorescence suggested abnormal lipofuscin clearance due to RPE dysfunction. The molecularly targeted therapy has revolutionized the cancer treatment and increased the survival rate. These agents are relatively new and recently approved for clinical use and most of them are associated with ocular toxicities. Awareness of ocular symptoms, side-effect profile of drugs, monitoring regime and liaison between oncologist and eye care professional with ocular imaging is key to early diagnosis and management of ocular adverse events.
Subject(s)
Macular Edema/diagnosis , Paraneoplastic Syndromes, Ocular/diagnosis , Photoreceptor Cells, Vertebrate/pathology , Retinal Diseases/diagnosis , Retinal Pigment Epithelium/pathology , Skin Neoplasms/pathology , Aged , Humans , Imidazoles/adverse effects , Imidazoles/therapeutic use , Macular Edema/chemically induced , Male , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Molecular Targeted Therapy , Oximes/adverse effects , Oximes/therapeutic use , Paraneoplastic Syndromes, Ocular/drug therapy , Photoreceptor Cells, Vertebrate/drug effects , Protein Kinase Inhibitors/adverse effects , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Pyridones/adverse effects , Pyridones/therapeutic use , Pyrimidinones/adverse effects , Pyrimidinones/therapeutic use , Retinal Diseases/chemically induced , Retinal Pigment Epithelium/drug effects , Subretinal Fluid , Tomography, Optical CoherenceABSTRACT
PURPOSE: To describe the rapid time course of visual and electroretinographic recovery from vitamin A deficiency in a patient with a history of multiple resected abdominal tumors, including ileal carcinoid and pancreatic adenocarcinoma. METHODS: A 61-year-old white man with a history of resected malignant ileal carcinoid and Stage III pancreatic adenocarcinoma referred with complaints of 6 weeks of difficulty with night vision. RESULTS: Initial testing showed significantly reduced scotopic rod responses in both eyes and decreased vitamin A levels and a normal cancer-associated retinopathy laboratory panel. He had complete recovery of both his symptoms and full-field electroretinography within 5 days of starting intramuscular vitamin A. CONCLUSION: Vitamin A deficiency-related retinopathy after abdominal surgery may be an underreported complication. This case provides a unique clinical perspective in our patient with a history of ileal carcinoid and Stage III pancreatic adenocarcinoma and confirms that rapid symptomatic and electroretinographic recovery is possible with appropriate treatment.
Subject(s)
Adenocarcinoma/complications , Carcinoid Tumor/complications , Ileal Neoplasms/complications , Night Blindness/etiology , Pancreatic Neoplasms/complications , Paraneoplastic Syndromes, Ocular/drug therapy , Vitamin A Deficiency/complications , Humans , Male , Middle Aged , Vitamin A/therapeutic use , Vitamins/therapeutic useABSTRACT
Opsoclonus myoclonus ataxia syndrome (OMAS) can be refractory to standard therapies and devastating. Alternative treatments are imperative. A 14-month-old male diagnosed with neuroblastoma and paraneoplastic OMAS achieved complete cancer remission with chemotherapy. The OMAS, however, persisted over the subsequent 4 years despite numerous immune-modulatory and immunosuppressive therapies. The patient ultimately achieved complete remission following therapeutic plasma exchange (TPE) combined with rituximab and intravenous immunoglobulin. After three asymptomatic years, he relapsed. Upon reintroducing TPE and rituximab plus oral prednisolone, the patient rapidly achieved a second complete remission. This case offers proof-of-principle for the potential efficacy of TPE for neuroblastoma-associated OMAS.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Neuroblastoma/drug therapy , Opsoclonus-Myoclonus Syndrome/therapy , Paraneoplastic Syndromes, Ocular/drug therapy , Plasma Exchange , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Humans , Infant , Male , Opsoclonus-Myoclonus Syndrome/chemically inducedABSTRACT
The authors report on two patients with bilateral acute exudative polymorphous paraneoplastic vitelliform maculopathy (AEPPVM) treated with intravitreal aflibercept (Eylea; Regeneron, Tarrytown, NY [marketed locally in Turkey by Bayer]). Underlying malignancy had been treated in each case, including breast carcinoma in one case and colon carcinoma in the other case. A macular vitelliform lesion was noted in the right eye and atrophic retinal pigment epithelial (RPE) changes were noted in the left eye of each case. Enhanced depth imaging optical coherence tomography (EDI-OCT) of the vitelliform lesion showed sensorineural retinal detachment, highly reflective subretinal material, ellipsoid loss in the right eye, and photoreceptor loss in both eyes of each patient. In both cases, the right eye with a vitelliform macular lesion was treated with intravitreal aflibercept (2.0 mg/0.05 mL) at monthly intervals for the first three injections and at bimonthly intervals for the following injections. Case 1 received a total of six injections and visual acuity (VA) increased from 20/70 to 20/50 at 10 months' follow-up. EDI-OCT showed slight gradual resolution of subretinal vitelliform material. Case 2 received three injections and VA increased from 20/100 to 20/40 at 4 months' follow-up with a decrease in the subretinal vitelliform deposit and intraretinal edema on EDI-OCT. Intravitreal aflibercept may control progression of APPVME in newly diagnosed cases by decreasing vascular leakage and stabilizing RPE function. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:844-850.].
Subject(s)
Angiogenesis Inhibitors/administration & dosage , Paraneoplastic Syndromes, Ocular/drug therapy , Receptors, Vascular Endothelial Growth Factor/administration & dosage , Recombinant Fusion Proteins/administration & dosage , Vitelliform Macular Dystrophy/drug therapy , Acute Disease , Aged , Female , Humans , Middle Aged , Treatment OutcomeSubject(s)
Autoimmune Diseases/drug therapy , Immunologic Factors/therapeutic use , Retinal Diseases/drug therapy , Rituximab/therapeutic use , Vision Disorders/drug therapy , Autoimmune Diseases/diagnosis , Autoimmune Diseases/physiopathology , Electroretinography , Evoked Potentials, Visual , Female , Fluorescein Angiography , Humans , Middle Aged , Paraneoplastic Syndromes, Ocular/drug therapy , Retinal Diseases/diagnosis , Retinal Diseases/physiopathology , Tomography, Optical Coherence , Vision Disorders/diagnosis , Vision Disorders/physiopathology , Visual FieldsABSTRACT
BACKGROUND: Paraneoplastic melanocytic proliferation (bilateral diffuse uveal melanocytic proliferation, BDUMP) is a rare but devastating disease that causes progressive visual loss in patients who usually have an occult malignancy. Visual loss occurs as a result of paraneoplastic changes in the uveal tissue. METHODS: In a masked fashion, the serum of two patients with BDUMP was evaluated for the presence of cultured melanocyte elongation and proliferation (CMEP) factor using cultured human melanocytes. We evaluated the efficacy of plasmapheresis as a treatment modality early in the disease in conjunction with radiation and chemotherapy. RESULTS: The serum of the first case patient was investigated after plasmapheresis and did not demonstrate proliferation of cultured human melanocytes. The serum of the second case was evaluated prior to treatment with plasmapheresis and did induce this proliferation. These findings are in accordance with the diminution of CMEP factor after plasmapheresis. Treatment with plasmapheresis managed to stabilise the ocular disease progression in both patients. CONCLUSIONS: In the past, visual loss due to paraneoplastic melanocytic proliferation was considered progressive and irreversible. We treated two patients successfully with plasmapheresis and demonstrated a relation between CMEP factor in the serum of these patients and proliferation of cultured melanocytes.
Subject(s)
Adenocarcinoma/secondary , Lung Neoplasms/pathology , Melanocytes/pathology , Paraneoplastic Syndromes, Ocular/diagnosis , Paraneoplastic Syndromes, Ocular/drug therapy , Adenocarcinoma/therapy , Aged , Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Bevacizumab , Cell Proliferation/drug effects , Combined Modality Therapy , Early Diagnosis , Fluorescein Angiography , Humans , Intravitreal Injections , Lung Neoplasms/therapy , Lymphatic Metastasis , Male , Paraneoplastic Syndromes, Ocular/etiology , Plasmapheresis , Subretinal Fluid , Tomography, Optical Coherence , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Visual Acuity/physiology , Visual Field Tests , Visual FieldsABSTRACT
BACKGROUND: Bilateral diffuse uveal melanocytic proliferation (BDUMP) is a paraneoplastic ocular syndrome occurring in patients with systemic, often occult but advanced carcinoma and is the hallmark of poor prognosis. Ocular signs precede manifestation of systemic carcinoma by 3-12 months, highlighting the need for appropriate index of suspicion and prompt evaluation. Treatment options for BDUMP are limited. Investigations are aimed at finding the occult primary malignancy, which can be challenging. Modalities for treatment of the ocular findings include corticosteroids, surgery, external beam radiotherapy, and treatment of the underlying malignant neoplasm. However, it is uncertain whether earlier intervention for the systemic malignancy will impact survival, as this paraneoplastic phenomenon is thought to occur in advanced malignancy. CASE PRESENTATION: We report a unique rare atypical case with BDUMP causing visual loss in a 62-year-old female as the presenting sign of central nervous system (CNS) B-cell lymphoma. Multiple grey or grey brown subretinal lesions with pigment clumps were present in both eyes on fundoscopy and multimodal imaging demonstrated multiple discrete lesions at the level of retinal pigment epithelium. Neuroimaging revealed presence of brainstem and cerebellopontine lesions suggestive of CNS lymphoma, which was further confirmed on biopsy. CONCLUSION: In the current atypical case, prompt diagnosis and immediate referral was key, with detailed systemic evaluation by an internist and oncologist. The reported case is distinct for the reason that BDUMP occurred secondary to primary CNS lymphoma, a hitherto unreported association.
Subject(s)
Lymphoma, B-Cell/complications , Paraneoplastic Syndromes, Ocular/complications , Paraneoplastic Syndromes, Ocular/diagnosis , Female , Fluorescein Angiography , Humans , Lymphoma, B-Cell/diagnosis , Middle Aged , Paraneoplastic Syndromes, Ocular/drug therapy , Tomography, Optical CoherenceABSTRACT
BACKGROUND: Sarcoid-like reactions have been reported and confirmed by histopathology in patients with malignant disease. This series demonstrates the complex relationship of malignancy and sarcoidosis as pertaining to the eye, which, to the best of our knowledge, has not been previously reported in the literature. METHODS: Retrospective case study of five patients with sarcoid-like reactions. Patients 1 to 4 represent patients with ocular sarcoid-like reaction and systemic malignant disease. Patient 5 had ocular malignancy and systemic sarcoid-like reaction; workup revealed renal cell cancer. For each patient, other etiologies of nonnecrotizing granulomatous inflammation were excluded. RESULTS: Sarcoid-like reactions have been described in the literature when nonnecrotizing granulomas occur in association with malignancy and in the absence of multiorgan involvement as seen with systemic sarcoid. In our series, sarcoid-like reactions involved the vitreous in three patients, retina in one patient, and the choroid and lung in one patient. Sarcoid-like reaction preceded the diagnosis of malignancy in two patients, was found concomitantly with malignancy in one patient, and followed malignancy in two patients. Two patients had hematologic malignancy, one patient had endometrial carcinoma, one had renal cell carcinoma, and one patient had both renal cell carcinoma and uveal melanoma. Four patients had findings of nonnecrotizing granulomas confirmed by histopathology. CONCLUSION: Sarcoid-like reactions can occur in the eye, and ocular malignancies may incite sarcoid-like reaction. Ocular sarcoid-like reactions have paraneoplastic features in that they can occur at a site distant from malignancy and may precede, occur simultaneously with, or follow malignancy.